Synonyms: Jinlitai® | JMT-103 | JMT103
narlumosbart is an approved drug (China (2023))
Compound class:
Antibody
Comment: Narlumosbart (JMT103) is a fully human IgG4κ anti-RANKL (receptor activator of nuclear factor kappa-Β ligand) monoclonal antibody. It blocks the RANK/RANKL protein-protein interaction and thereby reduces pathological osteoclastogenesis in bone cancer.
|
Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|